e-drug
[Top] [All Lists]

[e-drug] Barbados and Bolivia Submissions to the WHO/IGWG

E-DRUG: Barbados and Bolivia Submissions to the WHO/IGWG
-----------------------------------------------------------------------

Barbados and Bolivia have made an important submission to the WHO
Intergovernmental Working Group (IGWG) on Public Health, Innovation and
Public Health.

This includes a cover sheet (see below), and six proposals, including 5
R&D proposals involving innovation prizes (some of them fairly
detailed), and one proposal on the funding of clinical trials as global
public goods.

Four of the prize proposals are mechanisms where innovation prizes are
available to drug developers who voluntary license intellectual property
rights to patent pools.  As a novel feature, they also include rewards
for researchers who freely publish and share research, data and
technology that proves to be useful in successful products.  One of the
prize programs deals with access to cancer drugs in developing
countries.  The proposal on clinical trials as public goods elaborates
on an earlier IGWG proposal by Kenya, and submissions from academic
experts to the IGWG public forum.

jamie

-------------------
WORKING DOCUMENT
PROPOSED BY BARBADOS AND BOLIVIA
April 2008

According to resolution WHA60.30 on Public Health, Innovation and
Intellectual Property, the Director-General of the WHO is asked:

(4) to encourage the development of proposals for health-needs driven
research and development for discussion at the Intergovernmental Working
Group that includes a range of incentive mechanisms including also
addressing the linkage of the cost of research and development and the
price of medicines, vaccines, diagnostic kits and other health-care
products and a method for tailoring the optimal mix of incentives to a
particular condition or product, with the objective of addressing
diseases that disproportionately affect developing countries;

In this regard, Barbados and Bolivia are attaching for discussion six
proposals for the possible use of new incentive mechanisms for
innovation that separate linkages between rewards to innovation and the
price of medicines, vaccines, diagnostic kits and other health-care
products.

Each of the proposals attempt to address different solutions to promote
R&D on specific health issues:

Proposal 1: Prize Fund for Development of Low-Cost Rapid Diagnostic Test
for Tuberculosis. This is an example of the use of a prize fund to
address a discrete public health need.

Proposal 2: Prize Fund for the Development of New Treatments for Chagas
Disease. This is an example of how a prize fund might be designed to
increase treatments for a single neglected disease.

Proposal 3: Priority Medicines and Vaccines Prize Fund (PMV/pf). This is
a more ambitious proposal for a sustainable system of prizes to
stimulate innovation in four areas of public health need, including R&D
for Type III and Type II diseases, new antibiotics, and treatments for
emerging public health threats.

Proposal 4: Prizes as a Reward Mechanism for New Cancer Treatments. This
is a proposal for a sustainable system of rewards for an important Type
I disease, as it relates to the use of these products in developing
countries.

Proposal 5: Licensed Products Prize Fund (LP/pf) for Donors. This
proposal presents a possible  solution for donor-supported markets. It
would link an R&D reward system to voluntary agreements to license the
competitive supply of products for AIDS, TB and malaria and for other
humanitarian uses. This proposal would address the need for donors that
support humanitarian programs to have access to medicines at competitive
generic prices, while providing sustainable rewards to innovators.

In addition, we note that the WHO Member States have tentatively reached
consensus on a text  that agrees that there will be discussions about a
possible biomedical R&D treaty. In this regard, we also attach

Proposal 6: for a global agreement on the funding of clinical trials as
public  goods as one of the possible elements of such a treaty. The
proposal addresses the need for  government funding of clinical trials
that support the development of new drugs and vaccines, and also the
funding of independent trials for the evaluation of safety and
cost-effectiveness of existing products.

----------------------

Barbados and Bolivia have asked the WHO to put the proposals on the WHO
web site.  We have put copies of the proposals on the KEI web page here:


http://www.keionline.org/misc-docs/b_b_igwg/working_document_barbados_bolivia.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop1_tb_prize.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop2_chagas_prize.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop3_pmv_pf.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop4_cancer_prizes.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop5_donor_drugs_prizes.pdf
http://www.keionline.org/misc-docs/b_b_igwg/prop6_clinical_trials_as_as_global_public_goods.pdf



-- 
_____________________________
James Love, Knowledge Ecology International (KEI)
http://www.keionline.org, mailto:james.love@keionline.org
voice +1.202.332.2670, fax +1.202.332.2673, US mobile +1.202.361.3040, Geneva 
mobile +41.76.413.6584

When everyone thinks the same, no one thinks.  Bill Walton remix of Walter 
Lippmann



<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Barbados and Bolivia Submissions to the WHO/IGWG, James Love <=